Drug Trial Radar · NCT00792103
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
Last checked: Nov 19, 2026Latest source record: Feb 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
198
Actual
Start
Jan 2009
Primary completion
Sep 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- NuPathe Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by: * Subject self-examination skin irritation scores * Adverse events * Changes in vital signs and ECG parameters The secondary objective is to evaluate the long term efficacy of NP101 as assessed by: * Headache pain free at two hours after patch activation for all initial acute migraine attacks treated with NP101 * Headache pain relief at two hours after patch activation for all initial acute migraine attacks treated with NP101 * Nausea free at two hours after patch activation for all initial acute migraine attacks treated with NP101 * Phonophobia free at two hours after patch activation for all initial acute migraine attacks treated with NP101 * Photophobia free at two hours after patch activation for all initial acute migraine attacks treated with NP101 * Migraine free at two hours after patch activation for all initial acute migraine attacks treated with NP101 This study will use an open-label design to assess the long term safety of NP101 (sumatriptan iontophoretic transdermal patch). Subjects who continue to be in good health (use of a triptan or use of an NP101 patch is not contraindicated) and received treatment (patch activation) with the study patch for a qualifying migraine under study NP101-007 will be considered eligible for enrollment into the open-label study. Subjects will be expected to remain in the study for up to 12 months.
Conditions
- Migraine Disorders
Interventions
NP101Drug
NP101 study patch 4 hour application
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subject Self-examination of Skin IrritationTime frame: 24 hours post patch activation
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Little Rock, Arkansas
Site not named
Newport Beach, California
Site not named
San Francisco, California
Site not named
Santa Monica, California
Site not named
Fairfield, Connecticut
Site not named
Ocala, Florida
Site not named
Palm Beach Gardens, Florida
Site not named
Sunrise, Florida
Site not named
Atlanta, Georgia
Site not named
Columbus, Georgia
Site not named
Decatur, Georgia
Site not named
Savannah, Georgia
Site not named
Chicago, Illinois
Site not named
Ann Arbor, Michigan
Site not named
Kalamazoo, Michigan
Site not named
Springfield, Missouri
Site not named
St Louis, Missouri
Site not named
Mount Vernon, New York
Site not named
Plainview, New York
Site not named
Greensboro, North Carolina
Site not named
West Chester, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Philadelphia, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Wynnewood, Pennsylvania
Site not named
Memphis, Tennessee
Site not named
Nashville, Tennessee
Site not named
Dallas, Texas
Site not named
Houston, Texas
Site not named
San Antonio, Texas
Site not named
Alexandria, Virginia
Site not named
Virginia Beach, Virginia
Site not named
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.